|
Primate Diseases
|
C22.735 |
|
|
Tinea Favosa
|
C01.800.200.720.730.740 |
|
|
AMP-Activated Protein Kinases
|
D08.811.913.696.620.682.700.085 |
|
|
Patient Health Questionnaire
|
N06.850.520.308.980.485 |
|
|
Fluocortolone
|
D04.210.500.908.405 |
|
|
Heparan Sulfate Proteoglycans
|
D09.698.373.425.500 |
|
|
Heparitin Sulfate
|
D09.698.373.425 |
|
|
Secretoglobins
|
D060765 |
[A structurally-related family of small, multimeric proteins that are secreted in the mucosa of mammalian epithelial tissues. A variety of proteins are classed under this heading including some secretoglobin subtypes that appear unique to a particular mammalian species, and others whose functions differ between species.
] |
|
Drinking Water
|
D060766 |
[Water that is intended to be ingested.
] |
|
Head Protective Devices
|
J01.637.708.560.750 |
|
|
Microphthalmos
|
C16.131.384.666 |
|
|
Health Facility Merger
|
N02.278.235 |
|
|
Haploinsufficiency
|
G05.380.350.500 |
|
|
Gene Dosage
|
G05.380.350 |
|
|
Cross-Priming
|
D045142 |
[Class I-restricted activation of CD8-POSITIVE LYMPHOCYTES resulting from ANTIGEN PRESENTATION of exogenous ANTIGENS (cross-presentation). This is in contrast to normal activation of these lymphocytes (direct-priming) which results from presentation of endogenous antigens.
, Transfer of exogenous ANTIGEN to the ANTIGEN-PRESENTING CELLS for presentation to naive CD8-POSITIVE LYMPHOCYTES.
] |
|
Ataxia Telangiectasia Mutated Proteins
|
D08.811.913.696.620.682.700.097 |
|
|
Hip Fractures
|
C26.404.061.425 |
|
|
Femoral Fractures
|
C26.404.061 |
|
|
Therapeutic Irrigation
|
E02.779.492.500 |
|
|
Hydrotherapy
|
E02.779.492 |
|
